Viet Nam News
HCM CITY — A low bleeding rate of 1.5 per cent per year and low stroke rate of 1.7 per year were reported in atrial fibrillation patients in Asia who have used the non-vitamin K antagonist oral anti-coagulant (NOAC) of Bayer.
The data is from the full results of a study on the NOAC for Prevention of Stroke in Patients with Atrial Fibrillation in Asia, which was recently published in the Journal of Arrhythmia, the official publication of the Asia Pacific and Japan Heart Rhythm Societies.
This is the first and largest prospective study to date in Asia investigating the use of the non-vitamin K antagonist oral anti-coagulant in a broad patient population with the heart rhythm disorder, non-valvular atrial fibrillation (NVAF) across 10 Asian countries including Vietnam.
The study Principal Investigator, Prof Young-Hoon Kim, Korea University Medical Centre, Seoul, South Korea, said: “The prevalence of AF is growing in Asia, with an estimated 72 million patients by 2050. These patients will have a five-fold increased risk of stroke due to blood clots.
“While NOACs offer a new standard of care in preventing AF-related strokes, major bleeding is a key consideration for doctors when prescribing NOACs for AF patients. This data confirms the low bleeding risk of Bayer’s NOAC in Asian patients, thus reaffirming its positive benefit/risk profile, and demonstrates its value in preventing the negative impacts of stroke on patients and society.”
The study also reported that the rates of gastrointestinal (GI) bleeding and fatal intracranial (skull) bleeding in patients using the NOAC were relatively low at 0.5 per cent and 0.7 per cent per year respectively.
Over 96 per cent of patients in the study did not experience any major bleeding, stroke/systemic embolism (SE) or all-cause death.
The study included elderly patients with varying levels of stroke risk and significant medical co-morbidities including heart failure, hypertension, diabetes mellitus, prior stroke/ SE/transient ischemic attack and myocardial infarction.
This study adds to the robust experience and evidence that establish the safety profile of Bayer’s NOAC across patients with varying risk profiles.
“It is important to consider a patient’s individual risk factors to prescribe the right NOAC to the right patient for AF stroke prevention,” The study Principal Investigator, Prof Chia-Ti Tsai, National Taiwan University Hospital, Taipei, Taiwan, said.
“The NOAC’s robust experience and evidence in patients across different risk profiles, including those with high stroke risk, will best support doctors and patients in their treatment decision in AF management.
“The positive data of this study further adds to this and reaffirms the proven safety profile of the NOAC in Asian patients.”
The study followed 2,273 patients from 435 sites across Asia (Hong Kong SAR, Indonesia, South Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, Việt Nam and Pakistan) in routine clinical practice. — VNS